 AplaGen is committed to significant improvements for patients with dysfunctional bone marrow. Priority is given to peptides which mimic the action of important cytokines, especially erythropoietin (EPO) and thrombopoietin (TPO) .
Prognosis and quality of life of many patients depend on proper bone marrow function with appropriate production of red blood cells (EPO) and blood platelets (TPO).
Recombinant thrombopoietin is immunogenic and clinically useless. For recombinant EPOs there are restrictions of use in place. Priming a new class of cost-effectiv agents and combining this with an innovative clinical strategy, AplaGen is dedicated to overcome these limitations and to significantly improve prognosis and quality of life of patients with dysfunctional bone marrow, especially oncologic patients. Innovation Partnership
-
Does your competitor have a product in the market with a better half-life than your product? -
Are you looking for a method to improve binding properties and stability in vivo of your (peptide/protein) drug product? -
Would you like to optimize the pharmacokinetic profile of your peptide/protein product? -
Are you searching for expertise to optimize your peptide/protein product in the market prior to patent expiration and get novel IP for a second generation product? -
Are you developing/marketing a small molecule with significant toxicology, the benefit/risk ratio of which can profit from a change of its distribution volume by coupling to a macromolecule?
Then you should consider AplaGen's technologies, expertise and know-how. AplaGen offers a broad range of services. AplaGen‘s Innovation Partnership provides novel solutions for product differentiation, to enable superior pharmacological profiles and life-cycle management opportunities. The company’s HES-conjugation technology and peptide development capabilities represent the innovation potential that can be applied to both new and existing chemical and biological entities. The innovation partnership seeks co-development alliances with leading pharmaceutical and biotechnological companies.
|
